loader2
Partner With Us NRI

Kopran Ltd share Price Today

Company details

247.40
264.00
98.05
292.30
6M Return 11.13%
1Y Return 159.25%
Mkt Cap.(Cr) 1,246.74
Volume 446,183
Div Yield 1.16%
OI
-
OI Chg %
-
Volume 446,183

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Kopran Ltd shares SWOT Analysis

Strengths (9)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Companies with rising net profit margins - quarterly as well as TTM basis
  • Growth in Net Profit with increasing Profit Margin (QoQ)

Weakness (6)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • High Volume, High Gain

Threats (2)

  • Companies with growing costs YoY for long term projects
  • Increasing Trend in Non-Core Income

Resistance and support

R1 265.9
R2 273.3
R3 282.5
Pivot

256.67

S1 249.3
S2 240.1
S3 232.7
EMA SMA
253.2
255.0
249.3
231.5
250.8
257.9
256.4
229.2
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
QUANT MUTUAL FUND - QUANT SMALL CAP FUND Bulk Purchase 2024-03-15 255.41 250000 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-02-07 282.3 435689 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2024-02-07 282.33 435689 NSE
Name Category Shares
RAJENDRA SOMANI PROMOTER 3.66%
SUSHEEL SOMANI PROMOTER 1.81%
MRIDULA SOMANI PROMOTER 1.64%
SURENDRA SOMANI PROMOTER 1.24%
VANDANA SOMANI PROMOTER 0.67%
VARUN SOMANI PROMOTER 0.57%
NUPUR SOMANI PROMOTER 0.56%
JAYA SOMANI PROMOTER 0.54%
Oricon Enterprises Ltd PROMOTER 12.9%
Panorama Finvest Pvt Ltd PROMOTER 7.88%
Sarvamangal Mercantile Co. Ltd. PROMOTER 6.02%
UNITED SHIPPERS LTD PROMOTER 4.56%
PARIJAT SHIPPING AND FINALE LTD. PROMOTER 0.8%
G.CLARIDGE & COMPANY LIMITED PROMOTER 0.71%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Kopran Ltd Stocks COMPARISON

Financials( in Cr) Kopran Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 258.60 1,620.55 1,496.95 6,157.90 1,007.35
% Change 4.55 1.02 2.30 1.88 0.77
Mcap Cr 1,246.74 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 550.99 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr 27.23 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 30.87 41.45 30.52 19.64 30.51
1 Year Return 159.25 64.78 68.33 37.28 109.04
ROCE 8.17 16.79 14.76 25.99 16.25
ROE 6.29 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 439.25 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,068.81 33,709.58
LAST 3M 68,518.10 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,941.35 208,211.24

Kopran Ltd Information

Stock PE (TTM)
30.87
Promoter Holding
44.49%
Book Value
91.562
ROCE
8.17%
ROE
6.29%
Description
  • Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.`92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world`s highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran`s bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran`s high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce. The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda. The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002. The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres. The company has also increased its installed capacity of Tablets & Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos). In Feb. 2001, Kopran tied up with E-Merck for co-marketing a new anti-inflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fast-moving non-steroid anti-inflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin - a cholesterol reducer) and further gave co-marketing rights for Atorvastatin to E-Merck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004. Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 2014-15 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.

Registered Address

Parijat House 1076, Dr E Moses Road Worli, Mumbai, Maharashtra, 400018

Tel : 91-22-43661111
Email : sunil:kopran.com
Website : http://www.kopran.com
Registrar

Bigshare Services Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524280
NSE Code : KOPRAN
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE082A01010

FAQ’s on Kopran Ltd Shares

You can buy Kopran Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Kopran Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:50 PM the closing price of Kopran Ltd was ₹ 258.60.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:50 PM, the market cap of Kopran Ltd stood at ₹ 1,246.74.

The latest PE ratio of Kopran Ltd as of Mar 28, 2024 03:50 PM is 30.87

The latest PB ratio of Kopran Ltd as of Mar 28, 2024 03:50 PM is 0.35

The 52-week high of Kopran Ltd share price is ₹ 292.30 while the 52-week low is ₹ 98.05

Download Our

Download App
market app